Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

C. Krieckaert, B. Hernandez-Breijo, J.E. Gehin, G. le Meledo, A. Balsa, M. Jani, D. Mulleman, V. Navarro-Compan, G. Wolbink, J. Isaac, A. van Tubergen*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article numbere002216
Number of pages13
JournalRMD Open
Volume8
Issue number2
DOIs
Publication statusPublished - 1 Jun 2022

Keywords

  • Arthritis
  • Psoriatic
  • Rheumatoid
  • Biological Therapy
  • Pharmacokinetics
  • Spondylitis
  • Ankylosing
  • ANTI-ADALIMUMAB ANTIBODIES
  • LONG-TERM TREATMENT
  • SERUM INFLIXIMAB CONCENTRATIONS
  • SUCCESSFUL DOSE REDUCTION
  • CLINICAL-RESPONSE
  • ANKYLOSING-SPONDYLITIS
  • TROUGH LEVELS
  • PSORIATIC-ARTHRITIS
  • OPEN-LABEL
  • DOUBLE-BLIND

Cite this